Stifel Nicolaus began coverage on shares of Pyxis Oncology (NASDAQ:PYXS – Free Report) in a report published on Thursday, Marketbeat.com reports. The brokerage issued a buy rating and a $10.00 price target on the stock.
A number of other research firms have also recently weighed in on PYXS. HC Wainwright reaffirmed a buy rating and issued a $7.00 price objective on shares of Pyxis Oncology in a report on Thursday, May 16th. Jefferies Financial Group restated a buy rating and issued a $10.00 price target on shares of Pyxis Oncology in a research note on Tuesday, May 7th. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat, Pyxis Oncology presently has an average rating of Buy and an average target price of $9.00.
Read Our Latest Stock Report on PYXS
Pyxis Oncology Stock Down 5.5 %
Pyxis Oncology (NASDAQ:PYXS – Get Free Report) last released its quarterly earnings data on Saturday, May 11th. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.19. The company had revenue of $16.15 million during the quarter, compared to analysts’ expectations of $4.25 million. As a group, equities analysts anticipate that Pyxis Oncology will post -1.09 EPS for the current fiscal year.
Institutional Inflows and Outflows
Hedge funds have recently modified their holdings of the stock. Fullcircle Wealth LLC acquired a new stake in Pyxis Oncology in the 2nd quarter worth about $40,000. SG Americas Securities LLC purchased a new position in shares of Pyxis Oncology in the first quarter valued at approximately $59,000. Cetera Advisors LLC acquired a new stake in shares of Pyxis Oncology in the first quarter worth approximately $100,000. Schulhoff & Co. Inc. increased its position in shares of Pyxis Oncology by 90.9% during the second quarter. Schulhoff & Co. Inc. now owns 42,000 shares of the company’s stock worth $139,000 after purchasing an additional 20,000 shares in the last quarter. Finally, American Century Companies Inc. raised its stake in Pyxis Oncology by 56.0% in the 2nd quarter. American Century Companies Inc. now owns 58,252 shares of the company’s stock valued at $193,000 after purchasing an additional 20,901 shares during the last quarter. Institutional investors and hedge funds own 39.09% of the company’s stock.
About Pyxis Oncology
Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.
Featured Stories
- Five stocks we like better than Pyxis Oncology
- Investing in the High PE Growth Stocks
- Why Wall Street Analysts Raised Price Targets for Suncor Stock
- Why Invest in 5G? How to Invest in 5G Stocks
- Is Super Micro Computer a Buy After Shares Sink 20% on Earnings?
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- MarketBeat Week in Review – 8/5 – 8/9
Receive News & Ratings for Pyxis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pyxis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.